Trial Profile
Phase II open, single-center, pilot clinical trial to assess the pharmacokinetics, safety and tolerability, after the conversion of an immunosuppressive regimen with Prograf to prolonged release tacrolimus (Advagraf) in stable lung transplant patients [ENSAYO CLÍNICO DE FASE II, ABIERTO, UNICÉNTRICO, PILOTO PARA EVALUAR LAS CARACTERÍSTICAS FARMACOCINÉTICAS, SEGURIDAD Y TOLERABILIDAD, TRAS LA CONVERSIÓN DE UN RÉGIMEN INMUNOSUPRESOR CON PROGRAF A TACROLIMUS DE LIBERACIÓN PROLONGADA (ADVAGRAF) EN PACIENTES CON TRASPLANTE PULMONAR ESTABLE]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Tacrolimus (Primary)
- Indications Lung transplant rejection
- Focus Pharmacokinetics
- 09 Apr 2022 Status changed from recruiting to completed.
- 14 Jun 2011 New trial record